Background Primary vesicoureteral reflux (PVUR) is the most common malformation of the kidney and urinary tract, and reflux nephropathy is a major cause of chronic kidney disease in children. Recently, we reported mutations in the tenascin XB gene (TNXB) as a cause of PVUR with joint hypermobility. Methods To define the role of rare variants in tenascin genes in the etiology of PVUR, we screened a cohort of patients with familial PVUR (FPVUR) and non-familial PVUR (NFPVUR) for rare missense variants inTNXB and the tenascin C gene (TNC) after excluding mutations in ROBO2 and SOX17. Results The screening procedure identified 134 individuals from 112 families with PVUR; two families with mutations in ROBO2 were excluded from further analysis. Rare missense variants in TNXB were found in the remaining 110 families, of which 5/55 (9 %) families had FPVUR and 2/55 (4 %) had NFPVUR. There were no differences in high-grade reflux or renal parenchymal scarring between patients with and without TNXB variants. All patients with TNXB rare variants who were tested exhibited joint hypermobility. Overall we were able to identify causes of FPVUR in 7/57 (12 %) families (9 % in TNXB and 3 % in ROBO2). Conclusions In conclusion, the identification of a rare missense variant in TNXB in combination with a positive family history of VUR and joint hypermobility may represent a noninvasive method to diagnose PVUR and warrants further evaluation in other cohorts.
Introduction
Primary vesicoureteral reflux (PVUR) is the retrograde flow of urine from the bladder into the upper urinary tract due to an abnormal ureterovesical junction [1, 2] . It is the most common congenital anomaly of the kidneys and urinary tract (CAKUT) in children and is also the most important risk factor for pyelonephritis [2] . The prevalence of PVUR in children is estimated to be 1-2 % [3] , but this is likely an underestimate because of phenotypic heterogeneity and the lack of noninvasive diagnostic tools. In the pediatric age group untreated PVUR is the single most important risk factor for renal parenchymal scarring (RPS) [1, 2] . RPS due to PVUR (reflux nephropathy) is a major cause of end-stage kidney disease requiring dialysis and kidney transplantation in children [4] . Although the pathogenesis of PVUR has not been fully elucidated, it is believed to be a developmental anomaly due to a defect in the reciprocal signaling interaction between metanephric mesenchyme and the ureteric bud during kidney development [5] . This interaction is known to be controlled by a variety of genes during development, but the entire repertoire of genes involved remains unknown to date [5] . Although familial aggregation of PVUR has been reported in different studies, few loci have been identified for PVUR, and the genetic causes of familial PVUR are unknown in a large proportion of cases [6] [7] [8] . The variable penetrance of the disease often makes case ascertainment difficult and complex. In addition, the gold standard for diagnosing PVUR is a voiding cystourethrogram (VCUG), which requires catheterization of the child and radiation exposure, both undesirable interventions. Thus, ascertainment of large pedigrees with sufficient power for genome-wide linkage studies is often impossible. It is therefore not surprising that most of the loci that have been reported in the literature are from relatively small pedigrees, yielding findings that are inconclusive. We recently reported segregating mutations in the tenascin XB gene (TNXB) in a large kindred with PVUR and joint hypermobility [9] . The tenascin genes are a class of extracellular matrix proteins with a relatively similar structure, comprising N-terminal assembly and C-terminal fibrinogen-like domains, epidermal growth factor (EGF)-like repeats, and fibronectin III domains [10] [11] [12] . These fibronectin domains control cell adhesion and migration during development [13] .
The main objective of this study is to define the disease burden due to rare variants in TNXB and the tenascin C gene (TNC) in a cohort of children with PVUR and define the relationship between rare variants in tenascin genes, PVUR severity, and joint hypermobility. To this end, we screened 110 families with familial or non-familial PVUR for rare variants (minor allele frequency <0.01) in TNXB and TNC and obtained clinical data, including reflux grade and joint hypermobility score using the Beighton criteria [14] . We found rare missense variants in TNXB in 5/55 (9 %) families with PVUR and 2/55 (4 %) individuals with non-familial PVUR. We did not find any segregating rare variants in TNC. All of the rare variants in TNXB were predicted to be damaging by at least one in silico prediction software program. All three individuals with rare TNXB variants who had formal joint examination were found to have significant joint hypermobility. Rare variants in TNXB were found to be responsible for PVUR in 9 % of families with familial PVUR and 4 % of individuals with non-familial PVUR. These findings demonstrate that rare variants in TNXB and joint hypermobility may serve as a disease marker in familial PVUR and further reinforces the importance of genes encoding extracellular matrix proteins in the etiology and pathogenesis of PVUR.
Materials and methods

Clinical ascertainment
Study subjects were classified as previously described [9] . Briefly, study subjects were considered to be affected if they had VUR on a VCUG. Supportive evidence included history of recurrent urinary tract infection (UTI) and abnormal findings on renal ultrasonography. Individuals were considered to be unaffected if there was no detectable VUR on screening VCUG performed as part of routine clinical care or if they were un-related married individuals in the family. Individuals classified as unknown were those with a history of UTI but who had not undergone radiological investigations. We defined familial VUR as the presence of at least two individuals with radiologically confirmed VUR in the same family.
Mutation analysis
Genomic DNA was extracted from whole blood or saliva using standard methods. Mutation analysis was carried out by sequencing of both strands of all exons of TNXB, TNC, ROBO2, and SOX17 using exon-flanking primers; primer sequences are listed in Electronic Supplementary Material (ESM) Table 1. All sequences were analyzed with the Sequencher software (Gene Codes Corp, Ann Arbor, MI).
Stratification of variants and in silico prediction of impact of missense changes
All missense variants with a minor allele frequency of <0.01 were subjected to further analyses. In silico prediction of impact of amino acid substitution was determined using the SIFT [15] and Polyphen 2 [16] software. The impact of amino acid change on secondary structure of the protein was assessed by the I-TASSER server (http://zhanglab.ccmb.med.umich.edu/ I-TASSER/) housed at the University of Michigan, Ann Arbor, USA.
Joint examination for hypermobility
Joint examinations for hypermobility were carried out using the Beighton hypermobility score [14] . The examiners (CER and SE) were blinded to the detailed clinical and genotype data.
Data analysis
The clinical data and frequency of rare missense variants in TNXB, TNC, ROBO2, and SOX17 were compared between the familial and non-familial group. All categorical data were compared by the χ 2 test and Fisher's exact test where indicated, and a p value of <0.05 was considered to be significant.
Results
Clinical data
We identified 134 individuals with PVUR, of whom 79 individuals from 57 families were presumed to have familial VUR due to the presence of two or more affected individuals in the family. The study population was predominantly Caucasian, with 74/79 (94 %) of patients in the familial group and 48/55 (87 %) of patients in the non-familial group self-identifying as Caucasian. The majority (102/134, 76 %) of the cohort were female. There was no significant difference in age at diagnosis between familial and non-familial PVUR patients (Table 1) . Bilateral disease, distribution of reflux grades, and presence of renal parenchymal scarring (RPS) on dimercaptosuccinic acid (DMSA) scan were similar between the familial and the non-familial groups (Table 2) . Severe PVUR (VUR grade >3) was present in 31/79 (39 %) of the familial group and was similar in frequency to that in the non-familial group (14/55, 26 %) (Fisher's exact test, p=0.14).
Screening for mutations in ROBO2 and SOX17
Since mutations in ROBO2 and SOX17 have previously been associated with CAKUT and isolated VUR [17] [18] [19] [20] [21] , we screened the cohort for mutations in these genes and identified two families with segregating mutations in ROBO2 (Table 3; ESM Figs. 1, 2) and one individual with a rare variant in SOX17. The two mutations found in ROBO2 are novel and not present in any public database, they segregate with the disease in the two families, and they are predicted to be damaging by in silico prediction software [15, 16] . The pathogenicity of the SOX17 variant is unclear. We excluded individuals with ROBO2 mutations from further analysis of the tenascin genes.
Screening for rare variants in TNXB and TNC
Familial VUR
Genetic screening identified six segregating heterozygous rare variants in TNXB in 5/55 (9 %) families with familial VUR who did not carry mutations in ROBO2 or SOX17 ( Fig. 1 ; ESM Figs. 1, 2). We have previously reported two of these variants [c.9770C>T (T3257I) and c.3991G>A (G1331R) in families 6606 and 6952, respectively] [9] . All of the TNXB v a r i a n t s w e r e a n n o t a t e d using the transcript ENST00000375244 (ESM Fig. 3) . The rare variants identified were found in all seven affected individuals screened from the three new families (ESM Fig. 2) . All of the variants caused non-conservative amino acid changes which were predicted to be damaging by at least one in silico prediction software. Three of the six variants in the FPVUR families are not listed in the dbSNP, 1000 Genomes or NHLBI Exome Variant Server databases; the remaining three variants have been reported to have a low minor allele frequency of between 0.000 and 0.0002 in at least 6000 chromosomes. We also did not find any of the variants in at least 200 in-house ethnicity-matched control chromosomes (Table 3) . Interestingly, in one family (Fig. 2) . The phenotype associated with families with rare variants in TNXB is described in Table 4 . We did not find segregating variants in TNC in any of the families studied.
Non-Familial VUR
Since we were uncertain of the pathogenicity of the SOX17 variant found in one individual with non-familial VUR, we screened all 55 individuals with non-familial PVUR for rare variants in the two tenascin genes. We found rare variants [minor allele frequency (MAF) 0.008 and 0.0005, respectively] in TNXB in 2/55 (4 %) of patients in this cohort. Similar to the findings in the familial cohort, these two variants were predicted to be damaging by in silico modeling (Table 3) .
Joint hypermobility in TNXB rare variants
We previously reported that VUR co-segregates with joint hypermobility in a family with a TNXB mutation [9] . To provide further evidence that the rare variants we identified are likely to be pathogenic, we performed joint hypermobility testing on three individuals with rare variants in TNXB. All three individuals met the criteria for joint hypermobility with a Beighton score of ≥4 (Table 4) . 
Discussion
Primary vesicoureteral reflux is the most important risk factor for pyelonephritis and RPS in the pediatric age group [2] . Unlike other CAKUT, the genetic causes of PVUR are unknown in most cases [1] [2] [3] 22] . Mutations in ROBO2 and SOX17 have been reported as causes of isolated PVUR [17] [18] [19] [20] [21] , and more recently we reported mutations in TNXB as a cause of PVUR [9] . In the present study, we performed mutation analysis on ROBO2, SOX17, TNXB, and TNC in a cohort of patients with familial and sporadic PVUR. We found that rare variants in TNXB and ROBO2 account for 12 % (9 % TNXB, 3 % ROBO2) of all cases of familial PVUR in this cohort and that rare variants in TNXB account for 4 % of non-familial PVUR. Thus, based on this modest cohort, rare variants in TNXB appear to be the most common cause of autosomal dominant PVUR. Overall, we were able to identify a genetic cause of PVUR in 7/57 (12 %) families with familial PVUR. This is similar to the 7 % (47/650) prevalence in a cohort of 650 families with CAKUT reported by Hwang et al. [21] . In this latter study, the authors screened participants for mutations in 17 known dominant genes that have been associated with CAKUT in both humans and animal models [19] . It should be noted that the panel of 17 genes in the Hwang et al. study [21] did not include TNXB. We did not find differences in bilateral disease, high-grade reflux, or RPS between patients with familial and non-familial disease, possibly due to the limited sample size of our cohort, but we can provide no explanation based on our findings. We also did not have access to detailed prospective data on the history of recurrent UTI, therapy, and other factors that may influence outcome in PVUR in all of the patients in our cohort. Further analysis demonstrated that the prevalence of bilateral disease and high-grade reflux in the families with rare variants in TNXB is similar to that in the entire cohort. Most of the variants found in TNXB are likely to be pathogenic EGFL Epidermal growth factorlike because they segregate with the disease. Some are not in any public database and have extremely low MAF in the general population. In addition, all are predicted to be damaging by at least one in silico prediction software. Furthermore, all individuals with the TNXB variants who underwent joint mobility examination had significant joint hypermobility as assessed by the Beighton score [14] .
TNXB belongs to a family of large extracellular matrix proteins characterized by N-terminal assembly domains, EGF-like repeats, multiple fibronectin III domains, and a C-terminal fibrinogen-like domain [9] [10] [11] [12] [13] . This gene is expressed in kidneys and the urinary tract during development and is highly expressed at a critical period when the ureterovesical junction (UVJ) is being formed [9] . We did not find any specific clustering of the variants in particular exons or domains (Fig. 1) ; however, the majority of the variants (5/8) are located in the fibronectin III domains or linker regions between the fibronectin domains. The mechanism by which variants in TNXB cause PVUR has not been elucidated. However, we have shown in previous studies that fibroblast cell lines from an individual with a T3257I missense mutation in TNXB displayed reduced cell motility in response to platelet-derived growth factor and reduced expression of phosphorylated focal adhesion kinase, suggesting persistent and enhanced cell adhesion and defective disassembly of focal adhesion [9] . Future studies will address the mechanisms by which the variants may cause defective formation of the UVJ during development.
We did not find any possible disease-causing variants in >80 % of individuals with familial PVUR, thus further confirming that PVUR is genetically heterogeneous. There is significant need for further studies to identify other genetic causes of PVUR in order to develop a robust molecular diagnosis platform. The clinical implications of our findings suggest that the presence of PVUR and joint hypermobility in a child presenting in the clinic may warrant screening for rare missense variants in TNXB and other extracellular matrix protein genes in order to make a molecular diagnosis. If a pathogenic variant is identified in the index child presenting with PVUR, screening for rare missense variants in TNXB in asymptomatic family members may be sufficient to make a presumptive diagnosis of VUR.
In conclusion, familial PVUR is due to rare variants in TNXB and ROBO2 in 12 % of all families studied in this cohort. If the findings in this study are confirmed in an independent cohort, rare missense variants in TNXB and clinical findings such as joint hypermobility may represent a noninvasive diagnostic tool for PVUR. [9] b Joint hypermobility defined as Beighton score greater than or equal to 4
